Intermittent fasting - the future treatment in NASH patients?

Iulia Minciuna, Suchira Gallage, Mathias Heikenwalder, Shira Zelber-Sagi, Jean François Dufour

Research output: Contribution to journalReview articlepeer-review


NASH is one of the leading causes of chronic liver disease with the potential of evolving towards end-stage liver disease and HCC, even in the absence of cirrhosis. Apart from becoming an increasingly prevalent indication for liver transplantation in cirrhotic and HCC patients, its burden on the healthcare system is also exerted by the increased number of noncirrhotic NASH patients. Intermittent fasting has recently gained more interest in the scientific community as a possible treatment approach for different components of metabolic syndrome. Basic science and clinical studies have shown that apart from inducing body weight loss, improving cardiometabolic parameters, namely blood pressure, cholesterol, and triglyceride levels; insulin and glucose metabolism; intermittent fasting can reduce inflammatory markers, endoplasmic reticulum stress, oxidative stress, autophagy, and endothelial dysfunction, as well as modulate gut microbiota. This review aims to further explore the main NASH pathogenetic metabolic drivers on which intermittent fasting can act upon and improve the prognosis of the disease, and summarize the current clinical evidence.

Original languageEnglish
Pages (from-to)1290-1305
Number of pages16
Issue number4
StatePublished - 1 Oct 2023

Bibliographical note

Publisher Copyright:
© 2023 John Wiley and Sons Inc.. All rights reserved.

ASJC Scopus subject areas

  • Hepatology


Dive into the research topics of 'Intermittent fasting - the future treatment in NASH patients?'. Together they form a unique fingerprint.

Cite this